Gyroscope Therapeutics Limited
Clinical trials sponsored by Gyroscope Therapeutics Limited, explained in plain language.
-
Gene therapy injection for dry AMD shows promise in early trial
Disease control TerminatedThis study tested a single injection of a gene therapy called GT005 into the eye for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. The trial included 255 adults aged 55 and older. The goal was to see if the treatmen…
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 17, 2026 00:42 UTC
-
Experimental gene therapy for dry AMD shows early promise but study halted
Disease control TerminatedThis study tested a single injection of a gene therapy called GT005 for people with dry age-related macular degeneration (AMD), a leading cause of vision loss. The goal was to see if it was safe and could slow or stop the disease. The study was stopped early, so results are limit…
Phase: PHASE1, PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control TerminatedThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 10, 2026 13:24 UTC